During the last session, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s traded shares were 3.43 million, with the beta value of the company hitting 0.33. At the end of the trading day, the stock’s price was $1.94, reflecting an intraday gain of 3.19% or $0.06. The 52-week high for the IRWD share is $15.70, that puts it down -709.28 from that peak though still a striking 18.04% gain since the share price plummeted to a 52-week low of $1.59. The company’s market capitalization is $310.45M, and the average intraday trading volume over the past 10 days was 7.57 million shares, and the average trade volume was 2.94 million shares over the past three months.
Ironwood Pharmaceuticals Inc (IRWD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. IRWD has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.08.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Ironwood Pharmaceuticals Inc (IRWD) registered a 3.19% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.19% in intraday trading to $1.94, hitting a weekly high. The stock’s 5-day price performance is -8.06%, and it has moved by -48.54% in 30 days. Based on these gigs, the overall price performance for the year is -87.34%. The short interest in Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is 10.75 million shares and it means that shorts have 4.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 67.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $7 respectively. As a result, IRWD is trading at a discount of -260.82% off the target high and -157.73% off the low.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
In the rating firms’ projections, revenue will decrease -19.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 93.85M as predicted by 6 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 67.36M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 117.55M and 74.88M respectively. In this case, analysts expect current quarter sales to shrink by -20.16% and then drop by -10.04% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -28.37%. While earnings are projected to return 101.20% in 2025.
IRWD Dividends
Ironwood Pharmaceuticals Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders
Ironwood Pharmaceuticals Inc insiders own 1.81% of total outstanding shares while institutional holders control 102.46%, with the float percentage being 104.35%. BLACKROCK INC. is the largest shareholder of the company, while 306.0 institutions own stock in it. As of 2024-06-30, the company held over 22.88 million shares (or 14.5067% of all shares), a total value of $149.16 million in shares.
The next largest institutional holding, with 21.56 million shares, is of VANGUARD GROUP INC’s that is approximately 13.6737% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $140.59 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ironwood Pharmaceuticals Inc (IRWD) shares are Pacer Small Cap U.S. Cash Cows 100 ETF and iShares Core S&P Smallcap ETF . Data provided on Oct 31, 2024 indicates that Pacer Small Cap U.S. Cash Cows 100 ETF owns about 11.05 shares. This amounts to just over 6.90 percent of the company’s overall shares, with a $21.44 million market value. The same data shows that the other fund manager holds slightly less at 9.12, or about 5.70% of the stock, which is worth about $17.69 million.
